Biogen: Q4 Earnings Insights

Shares of Biogen BIIB decreased 0.7% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 45.08% over the past year to $4.58, which missed the estimate of $4.87.

Revenue of $2,852,600,000 decreased by 22.29% from the same period last year, which beat the estimate of $2,800,000,000.

Outlook

Biogen said it sees FY21 adjusted EPS of $17-$18.50 and sales of $10.45 billion-$10.75 billion.

How To Listen To The Conference Call

Date: Feb 03, 2021

Time: 08:00 AM

ET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1421476&tp_key=3db5323113

Price Action

Company's 52-week high was at $374.99

Company's 52-week low was at $223.25

Price action over last quarter: Up 3.36%

Company Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.